A new combination therapy regimen shows promising results for prostate cancer

TALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

Leave A Comment

Your email address will not be published. Required fields are marked *